- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | XuanZhu Biopharma-B: Annerazone Sodium New Indication Approved for Phase III Clinical Trial | 1 | AASTOCKS | ||
| Mi | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR NEW INDICATION OF ANAPRAZOLE SODIUM | 1 | HKEx | ||
| 09.04. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT - LICENSING AND SUPPLY AGREEMENT WITH BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB | 1 | HKEx | ||
| XUANZHU BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 30.03. | XUANZHUBIO-B (02575): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 27.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 27.03.2026 | 425 | Xetra Newsboard | The following instruments on XETRA do have their first trading 27.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 27.03.2026
Aktien
1 SE0006887451 Corline Biomedical AB
2... ► Artikel lesen | |
| 24.03. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT FINAL ANALYSIS RESULTS OF THE PHASE 3 CLINICAL STUDY (BRIGHT-2) OF BIREOCICLIB IN COMBINATION WITH FULVESTRANT ... | 3 | HKEx | ||
| 16.03. | XUANZHUBIO-B (02575): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.03. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT MARKETING APPROVAL FOR THE THIRD INDICATION OF XUANYUENING (BIREOCICLIB TABLETS) FOR THE FIRST-LINE TREATMENT ... | - | HKEx | ||
| 05.01. | XUANZHUBIO-B (02575): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 05.01. | XUANZHUBIO-B (02575): APPOINTMENT OF GENERAL MANAGER | - | HKEx | ||
| 02.01. | XUANZHUBIO-B (02575): RESIGNATION OF EXECUTIVE DIRECTOR AND GENERAL MANAGER | - | HKEx | ||
| 08.12.25 | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT SUCCESSFUL RENEWAL AND INCLUSION OF THE INNOVATIVE DRUG ANJIUWEI IN THE 2025 NRDL | 1 | HKEx | ||
| 08.12.25 | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT XUANYUENING, AN INNOVATIVE DRUG, FIRST INCLUDED IN THE NRDL | 5 | HKEx | ||
| 20.11.25 | XUANZHUBIO-B (02575): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 20.11.25 | XUANZHUBIO-B (02575): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS | 2 | HKEx | ||
| 17.11.25 | XUANZHUBIO-B (02575): INSIDE INFORMATION FILING WITH THE CSRC FOR PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 14.11.25 | XUANZHUBIO-B (02575): INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | - | HKEx | ||
| 28.10.25 | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT NG-350A GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | - | HKEx | ||
| 22.10.25 | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT OF PHASE III CLINICAL STUDY DATA OF BIREOCICLIB FOR FIRST-LINE TREATMENT OF HR+/HER2 - ADVANCED ... | 2 | HKEx |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,000 | -1,71 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,880 | +106,32 % | Psyence Biomedical Ltd.: Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| EVOTEC | 5,570 | +0,54 % | Mutares: Exklusiv-Interview - Deutz, Elmos, Evotec, Infineon und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,140 | +14,41 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| BIONTECH | 85,65 | +1,60 % | BioNTech-Aktie: Wann geht's wieder über 100 Euro? | BioNTech hat neue klinische Daten zu einem wichtigen Krebsmedikament veröffentlicht und damit erneut Fortschritte in seiner Onkologie-Pipeline demonstriert. Für Investoren sind solche Studiendaten entscheidend... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,725 | -0,67 % | Recursion-CEO erläutert KI-Strategie zur Beschleunigung der Medikamentenentwicklung | ||
| GENMAB | 240,90 | -3,02 % | Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 315,01 | -7,27 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,375 | +9,70 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| VALNEVA | 2,611 | -1,62 % | Guggenheim senkt Kursziel für Valneva-Aktie wegen Lyme-Impfstoff auf 11 US-Dollar | ||
| ADMA BIOLOGICS | 10,590 | -0,47 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| BEAM THERAPEUTICS | 30,155 | -1,70 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 6,670 | +13,92 % | Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update | In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was... ► Artikel lesen | |
| CG ONCOLOGY | 65,25 | -3,68 % | CG Oncology, Inc. - 8-K, Current Report | ||
| TYRA BIOSCIENCES | 34,990 | +0,14 % | This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday |
XUANZHU BIOPHARMACEUTICAL CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -8,50 % bei einem Aktienkurs von 3,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XUANZHU BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.